Why Vision Marine Technologies Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Shares of Vision Marine Technologies Inc (NASDAQ:VMAR) rose sharply in pre-market trading after the company announced financial results…
HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $15 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $15 price target.
ProPhase Labs Announces Plans To Initiate Clinical Trial Of Equivir, Goal To Launch Commercially In Q4 2023
ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase"), a growth oriented and diversified diagnostics, genomics and biotech company, today announced that its wholly-owned subsidiary, ProPhase BioPharma, Inc. (PBIO), is
ProPhase Labs Esophageal Cancer Early Detection Test (BE-smart) Featured in Peer-Reviewed Article in the International Journal of Molecular Science
To date, the BE-Smart test has been tested on over 200 human samples by mProbe Inc, a precision health and medicine company utilizing clinical proteomics in the oncology space, and has shown greater
HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $15 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $15 price target.
Prophase Labs’ Prophase Labs Will Acquiring New Equipment Which Is Expected To Double Its Current Capacity For Pouch Packaging By Q2 Of 2023. Pharmaloz Is Also Planning For Expansion Of Its Lozenge Manufacturing Business
Altogether, these expansion initiatives are expected to lead to a 200% increase in capacity for 2024 as compared to 2022. It is currently expected that the Pharmaloz expansion will be funded entirely from
HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $15 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $15 price target.
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of…
5 Value Stocks In The Healthcare Sector
The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices…
HC Wainwright & Co. Maintains Buy on ProPhase Labs, Raises Price Target to $15
HC Wainwright & Co. analyst Yi Chen maintains ProPhase Labs (NASDAQ:PRPH) with a Buy and raises the price target from $14 to $15.